Sparks commentary

Healthcare

Sparks

FDA approves Soleno Therapeutics’ (Nasdaq: SLN) Vykat XR
Published by Arron Aatkar, PhD

The US FDA has today approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release tablets. This marks the first FDA approved treatment to address hyperphagia in Prader-Willi syndrome, a rare neurodevelopmental condition (caused by a genetic abnormality) estimated to afflict one in every 15,000 babies in the US each year.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free